Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Sponsor
LIN YANG
Study ID
NCT06711471
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastric Cancer Adenocarcinoma Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab — DRUG
    Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).

Study Details

For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.

Key Dates

Start date
Nov 14, 2024
Status verified
Nov 2024
Primary completion
Nov 13, 2026
Completion
Nov 13, 2027

Study Design

Enrollment
31 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: trifluridine/tipiracil, bevacizumab, camrelizumab
    TAS-102 35mg/m² twice daily, orally on Days 1-5; Bevacizumab 5mg/kg intravenous infusion on Day 1; Camrelizumab 200mg intravenous infusion on Day 1; Repeat every 14 days.

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: 2 years ]

Central Contacts

Related Studies